Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab

Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab

Background Antibody-drug conjugates (ADC) are essential therapeutic options to treat solid and hematological cancers. The anti-epidermal growth factor-receptor (EGFR) antibody cetuximab (Cet) is used for the therapy of colorectal carcinoma (CRC). Anti-CRC Vδ2 cytolytic T lymphocytes can be elicited...

Full description

Saved in:
Bibliographic Details
Main Authors: Roberto Benelli, Alessandro Poggi, Delfina Costa, Laura Salvini, Samuele Tardito, Francesca Tosetti, Federico Villa, Maria Raffaella Zocchi
Format: Article
Language:English
Published: BMJ Publishing Group 2022-12-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/12/e005660.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items